Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.

被引：0
|
作者：
Sandhu, Shahneen Kaur
Violet, John A.
Ferdinandus, Justin
Thang, Sue-Ping
Iravani, Amir
Guo, Christina
Kong, Grace
Kumar, Aravind Ravi
Akhurst, Timothy J.
Beaulieu, Alexis
Murphy, Declan G.
Mooi, Jennifer
Tran, Ben
Toner, Guy C.
Williams, Scott
Hicks, Rodney J.
Hofman, Michael
机构：
[1] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Dept Canc Imaging, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Ctr, Dept Canc Surg, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5040
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5040
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC)
    Aragon-Ching, J. B.
    Jain, L.
    Draper, D.
    Gulley, J. L.
    Arlen, P. M.
    Wright, J. J.
    Jones, E.
    Chen, C. C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Gupta, S.
    Yang, Q.
    Halabi, S.
    Tubbs, A.
    Gore, Y.
    George, D. J.
    Nanus, D. M.
    Antonarakis, E. S.
    Danila, D.
    Szmulewitz, R.
    Wenstrup, R. J.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1165 - S1166
  • [43] PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.
    Morris, Michael J.
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Armour, Alison A.
    Messmann, Richard Adam
    Groaning, Michael
    Robarts, Adam
    Tolcher, Anthony W.
    Gordon, Michael S.
    Babiker, Hani M.
    Kuo, Phillip
    Kearney, Megan
    Jendrisak, Adam
    Wang, Yipeng
    Landers, Mark Andrew
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [44] Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer
    Ahmadzadehfar, Hojjat
    Eppard, Elisabeth
    Kuerpig, Stefan
    Fimmers, Rolf
    Yordanova, Anna
    Schlenkhoff, Carl Diedrich
    Gaertner, Florian
    Rogenhofer, Sebastian
    Essler, Markus
    ONCOTARGET, 2016, 7 (11) : 12477 - 12488
  • [45] First clinical results with Lu-177 PSMA-TUM1 for the treatment of castrate-resistant metastatic prostate cancer
    Kulkarni, Harshad
    Weineisen, M.
    Mueller, Dirk
    Schuchardt, Christiane
    Schottelius, Margret
    Wester, Hans
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [46] Gemcitabine and Docetaxel in Metastatic, Castrate-Resistant Prostate Cancer Results From a Phase 2 Trial
    Garcia, Jorge A.
    Hutson, Thomas E.
    Shepard, Dale
    Elson, Paul
    Dreicer, Robert
    CANCER, 2011, 117 (04) : 752 - 757
  • [47] Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
    Morris, Michael J.
    De Bono, Johann S.
    Chi, Kim N.
    Fizazi, Karim
    Herrmann, Ken
    Rahbar, Kambiz
    Tagawa, Scott T.
    Nordquist, Luke T.
    Vaishampayan, Nitin
    El-Haddad, Ghassan
    Park, Chandler H.
    Beer, Tomasz M.
    Perez-Contreras, Wendy J.
    Desilvio, Michelle
    Kpamegan, Euloge E.
    Gericke, Germo
    Messmann, Richard Adam
    Krause, Bernd J.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
  • [48] Efficacy and safety of Lutetium-177 PSMA radioligand therapy versus Docetaxel in metastatic castration resistant prostate cancer - preliminary results of a randomized controlled trial
    Satapathy, Swayamjeet
    Mittal, Bhagwant
    Sood, Ashwani
    Bhattacharya, Anish
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
  • [49] Impact of pre-treatment hemoglobin (Hgb) on outcomes in metastatic castration resistant prostate cancer (mCRPC) with lutetium-177-PSMA-617 (Lu-177)
    Nelson, Ariel Ann
    Riemersma, Kristin
    Bylow, Kathryn A.
    Holt, Michael
    Kilari, Deepak
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Sandhu, Shahneen
    Joshua, Anthony M.
    Emmett, Louise
    Spain, Lavinia Anne
    Horvath, Lisa
    Crumbaker, Megan
    Anton, Angelyn
    Wallace, Roslyn
    Pasam, Anupama
    Bressel, Mathias
    Cassidy, Erin
    Banks, Patricia
    Dhiantravan, Nattakorn
    Akhurst, Timothy J.
    Kumar, Aravind Ravi
    Alipour, Ramin
    Scalzo, Mark
    Williams, Scott
    Hicks, Rodney
    Hofman, Michael S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345